These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 31138176

  • 21. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
    Wu D, Hiroshima K, Yusa T, Ozaki D, Koh E, Sekine Y, Matsumoto S, Nabeshima K, Sato A, Tsujimura T, Yamakawa H, Tada Y, Shimada H, Tagawa M.
    Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
    [Abstract] [Full Text] [Related]

  • 22. Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series.
    Broggi G, Massimino M, Failla M, Filetti V, Rapisarda V, Ledda C, Lombardo C, Loreto C, Vigneri P, Caltabiano R.
    Pathol Res Pract; 2024 Jul; 259():155350. PubMed ID: 38781764
    [Abstract] [Full Text] [Related]

  • 23. Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.
    Minami K, Jimbo N, Tanaka Y, Hokka D, Miyamoto Y, Itoh T, Maniwa Y.
    Virchows Arch; 2020 Mar; 476(3):469-473. PubMed ID: 31667596
    [Abstract] [Full Text] [Related]

  • 24. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A.
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [Abstract] [Full Text] [Related]

  • 25. Whole-Genome Comparative Copy Number Alteration Profiling between Malignant Pleural Mesothelioma and Asbestos-Induced Chronic Pleuritis.
    Tuncel T, Metintas M, Güntülü AK, Güneş HV.
    J Environ Pathol Toxicol Oncol; 2024 Jan; 43(1):31-44. PubMed ID: 37824368
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.
    Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
    [Abstract] [Full Text] [Related]

  • 29. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
    Borczuk AC, Pei J, Taub RN, Levy B, Nahum O, Chen J, Chen K, Testa JR.
    Cancer Biol Ther; 2016 Feb; 17(3):328-35. PubMed ID: 26853494
    [Abstract] [Full Text] [Related]

  • 30. Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.
    Bruno R, Alì G, Poma AM, Proietti A, Libener R, Mariani N, Niccoli C, Chella A, Ribechini A, Grosso F, Fontanini G.
    J Mol Diagn; 2020 Apr; 22(4):457-466. PubMed ID: 32036091
    [Abstract] [Full Text] [Related]

  • 31. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
    Matsumoto S, Nabeshima K, Kamei T, Hiroshima K, Kawahara K, Hata S, Marukawa K, Matsuno Y, Taguchi K, Tsujimura T.
    Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
    [Abstract] [Full Text] [Related]

  • 32. Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients.
    Nymark P, Aavikko M, Mäkilä J, Ruosaari S, Hienonen-Kempas T, Wikman H, Salmenkivi K, Pirinen R, Karjalainen A, Vanhala E, Kuosma E, Anttila S, Kettunen E.
    Mol Oncol; 2013 Feb; 7(1):29-40. PubMed ID: 22901466
    [Abstract] [Full Text] [Related]

  • 33. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
    Brcic L, Le Stang N, Gallob F, Pissaloux D, Sequeiros R, Paindavoine S, Pairon JC, Karanian M, Dacic S, Girard N, Churg A, Tirode F, Galateau-Salle F.
    Arch Pathol Lab Med; 2023 Mar 01; 147(3):313-322. PubMed ID: 35738002
    [Abstract] [Full Text] [Related]

  • 34. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S, Viberti C, Cugliari G, Allione A, Casalone E, Betti M, Ferrante D, Aspesi A, Casadio C, Grosso F, Libener R, Piccolini E, Mirabelli D, Dianzani I, Magnani C, Matullo G.
    J Thorac Oncol; 2019 Mar 01; 14(3):527-539. PubMed ID: 30408567
    [Abstract] [Full Text] [Related]

  • 35. The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?
    Kulduk G, Ekinci Ö, Toker G, Demirci U, Özaydın E, Akyürek N, Memiş L.
    Pathol Res Pract; 2019 Jun 01; 215(6):152377. PubMed ID: 30885529
    [Abstract] [Full Text] [Related]

  • 36. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma.
    Murthy SS, Testa JR.
    J Cell Physiol; 1999 Aug 01; 180(2):150-7. PubMed ID: 10395284
    [Abstract] [Full Text] [Related]

  • 37. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.
    Fujii M, Fujimoto N, Hiraki A, Gemba K, Aoe K, Umemura S, Katayama H, Takigawa N, Kiura K, Tanimoto M, Kishimoto T.
    Cancer Sci; 2012 Mar 01; 103(3):510-4. PubMed ID: 22146010
    [Abstract] [Full Text] [Related]

  • 38. Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study.
    Crovella S, Bianco AM, Vuch J, Zupin L, Moura RR, Trevisan E, Schneider M, Brollo A, Nicastro EM, Cosenzi A, Zabucchi G, Borelli V.
    J Toxicol Environ Health A; 2016 Mar 01; 79(3):129-41. PubMed ID: 26818092
    [Abstract] [Full Text] [Related]

  • 39. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G.
    J Thorac Oncol; 2018 Feb 01; 13(2):258-272. PubMed ID: 29113949
    [Abstract] [Full Text] [Related]

  • 40. Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.
    Lin RT, Chang YY, Wang JD, Lee LJ.
    J Formos Med Assoc; 2019 Jan 01; 118(1 Pt 3):463-470. PubMed ID: 30072200
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.